Immutep (IMMP) announces positive data from the EFTISARC-NEO trial that were detailed in an oral presentation by Pawe Sobczuk, M.D., Ph.D., Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland, at the Connective Tissue Oncology Society, CTOS, 2025 Annual Meeting held in Boca Raton, Florida. The investigator-initiated Phase II study evaluating eftilagimod alfa with radiotherapy plus KEYTRUDA in the neoadjuvant setting for resectable soft tissue sarcoma significantly exceeded the study’s prespecified level of pathologic response rates. In the evaluable patient population, the novel combination with efti reached a median 51.5% tumour hyalinization/fibrosis, meeting the study’s primary endpoint.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMP:
- Immutep Secures A$4.6 Million R&D Incentive from French Government
- Immutep receives EUR 2,588,954 R&D tax incentive from French Government
- Immutep Advances Key Clinical Trials and Strengthens Financial Position
- Immutep reports Q1 cash receipts from customers A$15,000
- Immutep Showcases Promising Lung Cancer Treatment Results at ESMO Congress 2025